|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is human hepatocellular carcinoma a hormone-responsive tumor?显示文摘Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib,there was no standard systemic treatment for patients with advanced hepatocellular carcinoma(HCC).Sex hormones receptors are expressed in a significant proportion of HCC samples.Following preclinical and epidemiological studies supporting a relationship between sex hormones and HCC tumorigenesis,several randomized controlled trials (RCTs)tested the efficacy of the anti-estrogen tamoxifen as systemic treatment.Largest among these trials showed no survival advantage from the administration of tamoxifen,and the recent Cochrane systematic review produced a completely negative result.This questions the relevance of estrogen receptor-mediated pathways in HCC.However,a possible explanation for these disappointing results is the lack of proper patients selection according to sex hormones receptors expression,but unfortunately the interaction between this expression and efficacy of tamoxifen has not been studied adequately.It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway,that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative.Interesting,preliminaryresults have been obtained when hormonal treatment (tamoxifen or megestrol)has been selected according to the presence of wild-type or variant estrogen receptors respectively,but no large RCTs are available to support this strategy.Negative results have been obtained also with anti-androgen therapy.In conclusion,there is no robust evidence to consider HCC a hormone-responsive tumor.Hormonal treatments should not be part of the current management of HCC. | Massimo Di Maio Bruno Daniele Sandro Pignata Ciro Gallo Ermelinda De Maio Alessandro Morabito Maria Carmela Piccirillo Francesco Perrone | 2008 | World Journal of Gastroenterology2008，14，11： | 2 |
| 2 | Chemotherapy in epithelial ovarian cancer显示文摘 | Sandro Pignata Lucia Cannella Davide Leopardo | 2011 | Cancer Lett2011，303，： | 1 |
| 3 | Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients显示文摘 | Steven A. Curley Paolo Marra Karen Beaty Lee M. Ellis J Nicolas Vauthey Eddie K. Abdalla Courtney Scaife Chan Raut Robert Wolff Haesun Choi Evelyne Loyer Paolo Vallone Francesco Fiore Fabrizio Scordino Vincenzo De Rosa Raffaele Orlando Sandro Pignata Brun | 2004 | Annals of Surgery2004，，4： | 1 |
| 4 | Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial显示文摘 | Sandro Pignata Giovanni Scambia Dionyssios Katsaros Ciro Gallo Eric Pujade-Lauraine Sabino De Placido Alessandra Bologna Beatrice Weber Francesco Raspagliesi Pierluigi Benedetti Panici Gennaro Cormio Roberto Sorio Maria Giovanna Cavazzini Gabriella Ferran | 2014 | Lancet Oncology2014，，： | 1 |
| 5 | Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells显示文摘 | Alessandro Ottaiano Antonella di Palma Maria Napolitano Carmen Pisano Sandro Pignata Fabiana Tatangelo Gerardo Botti Angela Maria Acquaviva Giuseppe Castello Paolo Antonio Ascierto Rosario Vincenzo Iaffaioli Stefania Scala | 2005 | Cancer Immunology Immunotherapy2005，，8： | 1 |
| 6 | Chemotherapy in epithelial ovarian cancer显示文摘 | Sandro Pignata Lucia Cannella Davide Leopardo Carmela Pisano Giovanni Salvatore Bruni Gaetano Facchini | 2011 | Cancer Letters2011，，2： | 1 |
| 7 | Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor:A tertiary care experience显示文摘Objective Post-chemotherapy retroperitoneal lymph node dissection(PC-RPLND)represents an integral component of the management of patients with non-seminomatous germ cell tumor(NSGCT).Modified templates have been proposed to minimize the surgical morbidity of the procedure.Moreover,the implementation of robotic surgery in this setting has been explored.We report our experience with unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection(PC-rRPLND)for clinical Stages IIA and IIB NSGCTs.Methods A retrospective single institution review was performed including 33 patients undergoing PC-rRPLND for Stages IIA and IIB NSGCTs between January 2015 and February 2019.Following orchiectomy,patients were scheduled for chemotherapy with three cycles of bleomycin-etoposide-cisplatin.Patients with a residual tumor of<5 cm and an ipsilateral metastatic disease on pre-and post-chemotherapy CT scans were eligible for a unilateral template in absence of rising tumor markers.Descriptive statistics were provided for demographics,clinical characteristics,intraoperative and postoperative parameters.Perioperative,oncological,and functional outcomes were recorded.Results Overall,7(21.2%)patients exhibited necrosis or fibrosis;14(42.4%)had mature teratoma;and 12(36.4%)had viable tumor at final histology.The median lymph node size at surgery was 25(interquartile range[IQR]21-36)mm.Median operative time was 180(IQR 165-215)min and no major postoperative complications were observed.Anterograde ejaculation was preserved in 75.8%of patients.Median follow-up was 26(IQR 19-30)months and a total of three recurrences were recorded.Conclusion PC-rRPLND is a reliable and technically reproducible procedure with safe oncological outcomes and acceptable postoperative ejaculatory function in well selected patients with NSGCTs. | Dario Franzese Antonio Tufano Alessandro Izzo Raffaele Muscariello Giovanni Grimaldi Giuseppe Quarto Luigi Castaldo Sabrina Rossetti Savio Domenico Pandolfo Sonia Desicato Paola Del Prete Matteo Ferro Sandro Pignata Sisto Perdonà | 2023 | Asian Journal of Urology2023，10，4： | 0 |
| 8 | 奥拉帕利维持治疗BRCA 1/2突变铂敏感复发性卵巢癌患者(SOLO2/ENGOT-Ov21):一项双盲随机对照Ⅲ期试验的最终分析显示文摘背景既往发表的SOLO2/ENGOT-Ov21试验的第一部分研究结果表明,作为BRCA1或BRCA2(BRCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者总生存期的影响。方法本研究是一项在16个国家123个医疗中心进行的双盲、随机、安慰剂对照、Ⅲ期临床试验。纳入标准包括:年龄≥18岁;ECOG体能状态评分基线水平为0~1分;组织学检查确诊为复发性、高级别浆液性或高级别子宫内膜样卵巢癌,包括原发性腹膜癌或输卵管癌;以及既往接受过2种或2种以上铂类药物的治疗方案。入选患者按2∶1分配到奥拉帕利组(150 mg片剂,每日2次口服,共300 mg)或安慰剂组;根据既往化疗后是否缓解以及无铂治疗间隔时长进行分层;受试者、治疗提供者和数据分析人员在治疗分配时均设盲。主要终点是既往已报道过的无进展生存期;总生存期作为重要的次要终点之一,在所有随机分配的患者中进行分析;安全性评估在至少接受过1次给药的所有患者中进行。结果2013年9月3日—2014年11月21日,共295例患者参与了试验并被随机分到奥拉帕利组(196例,66%)或安慰剂组(99例,34%)治疗。奥拉帕利组患者中位随访时间为65.7个月(IQR:63.6~69.3),安慰剂组为64.5个月(IQR:63.4~68.7)。奥拉帕利组中位总生存期为51.7个月(95%CI:41.5~59.1),安慰剂组为38.8个月(95%CI:31.4~48.6)(HR=0.74,95%CI:0.54~1.00,P=0.054)。安慰剂组38%接受PARP抑制剂治疗的患者未作调整。治疗引发的最常见的Ⅲ级以上不良事件为贫血,奥拉帕利组发生率为21%(41/195),安慰剂组为2%(2/99)。 | Andrés Poveda Anne Floquet Jonathan A Ledermann Rebecca Asher Richard T Penson Amit M Oza Jacob Korach Tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni Tjoung-Won Park-Simon Kenji Tamura Gabe S Sonke Alla Lisyanskaya Jae-Hoon Kim Elias Abdo Filho Tsveta Milenkova Elizabeth S Lowe Phil Rowe Ignace Vergote Eric Pujade-Lauraine the SOLO/ENGOT-Ovinvestigators 王娟(校) 李征(校) | 2021 | 肿瘤药学2021，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员